Ponatinib Monotherapy in adult patients with Relapsed or Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia: A Real-World Retrospective Analysis Including MRD Relapse.
Sign Up to like & getrecommendations! Published in 2025 at "Acta haematologica"
DOI: 10.1159/000548544
Abstract: INTRODUCTION The treatment of relapsed or refractory (R/R) Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) remains challenging after failure to several tyrosine kinase inhibitors. This study evaluated the clinical outcomes of ponatinib in a real-world… read more here.
Keywords: relapse; mrd relapse; response; ponatinib ... See more keywords
Single-Cell Multi-Omic Analysis of AML MRD Reveals Differences in Clonal Architecture between Relapse and Non-Relapse Cases
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-210840
Abstract: Introduction The Mission Bio AML single-cell MRD assay quantitatively characterizes SNVs and surface protein expression simultaneously across thousands of individual cells. In contrast, bulk NGS requires averaging across the entire population, preventing co-localization of joint… read more here.
Keywords: relapse; single cell; mrd relapse; aml ... See more keywords
Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-794
Abstract: Introduction: The FLAIR (ISRCTN01844152) phase III trial for previously untreated fit CLL patients showed that measurable residual disease (MRD)-guided ibrutinib-venetoclax (I+V) significantly improved response, progression-free survival (PFS), and overall survival (OS) compared to ibrutinib-alone (IBR)… read more here.
Keywords: treatment; mrd eot; mrd relapse; cll ... See more keywords